Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study
Key facts
- Who runs it
- Indiana University
- Where
- Indianapolis and Portland, United StatesSee the 3 sites
- Trial code
- Status
- Terminated
- People taking part
- 18 people enrolled
- Started
- 12 Dec 2019
- Ended
- 20 Feb 2024
- Type of study
- Interventional
- Treatments tested
- Reduced Dose SRS
- Record updated
- 13 February 2025
- Why it stopped
- trial stopped due to low accrual
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Brain MRI-confirmed 1-10 solid tumor brain metastases
- Biopsy-confirmed primary malignancy
- ds-GPA estimated median survival of at least 6 months, for histologies not included in the ds-GPA, publications or noted online at brainmetgpa.com, the PI will use either published or validated data or their best clinical judgment to determine the patient's expected survival
- Stereotactic radiosurgery candidate per treating Radiation Oncologist
- ≥ 18 years old at the time of informed consent
- Ability to provide written informed consent and HIPAA (Health Insurance Portability and Accountability Act) authorization
- ALC > 800/ul (Ku et al., 2010)
- Patients currently on cytotoxic chemotherapy are eligible
- Patients receiving ICI up to 30 days prior to delivery of SRS are eligible
- Patients having undergone operative resection for metastatic brain disease within 30 days of immune checkpoint inhibitor (ICI) administration are eligible
Who cannot take part
- Previous whole brain radiation therapy
- For Cohort 1: Previous stereotactic radiosurgery where the 50% isodose line overlaps with current treatment field
- For Cohort 2: Patients whose treatment will have a dose overlap within the target from prior treatments of 20% or greater
- Already receiving chronic dexamethasone (chronic = > 2 weeks) prior to SRS
- Not a radiosurgical candidate per Radiation Oncology discretion
- Major medical illnesses or psychiatric impairments, which in the investigator's opinion will prevent administration or completion of the protocol therapy and/or interfere with follow-up
- Total volume of metastatic disease more than 30 cubic centimeters
- Existing autoimmune disease
- Patients who have an unknown primary cancer
- Histology not amenable for SRS (i.e. lymphoma). (Small Cell Lung Cancer IS amenable.)
- Patients unable to receive MRI Brain
- Patients with more than 10 brain metastases on MRI Brain imaging
- Any lesion > 4 centimeter maximum diameter
Where in United States
- Indiana University Health HospitalIndianapolis, United States
- Indiana University Methodist HospitalIndianapolis, United States
- Oregon Health and SciencesPortland, United States
About the trial
What the trial wants to find out
This study will evaluate the rate of radiation necrosis following treatment with immune checkpoint inhibitor (ICI) treatment and radiation therapy in subjects with metastatic brain cancer. Subjects will be treated with the standard of care immunotherapy followed by radiation therapy via stereotactic radiosurgery at a reduced dose.
The group in the trial
- Reduced Dose Stereotactic RadiosurgeryTreatment being tested
Subjects will receive one stereotactic radiosurgery (SRS) treatment at a reduced dose based on the brain tumor size concurrently with their standard of care immunotherapy. Subjects will undergo follow up with clinical exams and brain MRI scans at 1, 3, 6, 9, and 12 months post SRS treatment
Treatment: Reduced Dose SRS
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): A prospective phase I study protocol.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2020
- Record updated
- 13 February 2025